Delta-like and Jagged family Notch ligand (null)

Notch ligands are type 1 transmembrane proteins in the Delta/Serrate/Lag-2 (DSL) family, subdivided in mammals as Delta-like (DLL1, DLL3, DLL4) and Serrate-like (Jagged1, Jagged2) ligands[8][4]. They are essential mediators of the highly conserved Notch signaling pathway, regulating direct cell-cell communication that governs cell fate, differentiation, proliferation, and tissue patterning across embryonic development and adult tissue maintenance[4][8]. Notch ligands consist of an N-terminal C2 (lipid-binding) domain, the conserved DSL domain responsible for Notch receptor binding, and multiple EGF-like repeats that contribute to molecular diversity and modulate binding affinity[2][9]. Upon binding to Notch receptors (NOTCH1-4) on adjacent cells, the ligands trigger a cascade of proteolytic cleavages in the receptor, resulting in the release of the Notch intracellular domain and the activation of Notch-responsive genes in the nucleus[6][9]. Aberrant Notch ligand expression or function is implicated in diverse diseases, especially in oncogenesis (notably hematologic malignancies, solid tumors), congenital syndromes, and cardiovascular pathologies[8][4]. Targeting Notch ligands (especially DLL3, DLL4, and Jagged1/2) with antibodies and other pharmacological agents is an active area of drug development, although toxicities from interfering with normal Notch-dependent processes remain a significant challenge[8][4]. Note: "Notch ligand" is a class rather than a single molecule. For structured data, specific ligands (e.g., DLL4, Jagged1) can be delineated as needed.

Other names

Delta-like ligand (DLL1, DLL3, DLL4)Jagged1Jagged2Serrate-like ligandDSL ligandNotch ligand

Ligand inhibition: therapeutic antibodies block the interaction between Notch ligands and Notch receptors, preventing activation of the Notch signaling pathway - Pathway modulation: by blocking ligand binding, downstream transcriptional activation of Notch target genes is reduced